Business
Easton Pharmaceuticals & Partner BMV Medica Announce Delivery and Launch of AmnioSense (AL-Sense) in Mexico; Delivery Date for Purchase Order From Windsor Pharmaceuticals for Central America
Easton Pharmaceuticals & Partner BMV Medica Announce Delivery and Launch of AmnioSense (AL-Sense) in Mexico; Delivery Date for Purchase Order From Windsor Pharmaceuticals for Central America.
About this update from Easton Pharmaceuticals Inc
[{"type":"text","content":"\n\n TORONTO, ON, Dec. 06, 2017 (GLOBE NEWSWIRE) --  Easton Pharmaceuticals Inc. (OTC: EAPH) and its JV partner, BMV Medica SA de CV, announces product delivery and launch of its licensed AmnioSense (AL-Sense) product from its previously announced Gedeon Richter distribution agreement for Mexico. Easton/BMV is also expecting delivery this week of initial Purchase Order for Central America with exclusive Distribution Partner, Windsor Pharmaceuticals, with launch in initial countries in Central America by February, 2018.\n Per its previously announced sub-licensing agreement executed with Gedeon Richter SA de CV, a Mexican subsidiary of Gedeon Richter SA of Hungary, Easton / BMV have been notified that after delays on items including importation permits, AmnioSense has been delivered in Mexico and has launched in the Mexico market. In addition, after filing the regulatory documents subsequent to a signed sub-licensing agreement with Panama- based Windsor Pharmaceuticals, Easton and BMV Medica previously received confirmation that Windsor Pharmaceuticals received government regulatory approval to begin the marketing and selling of products “VS-Sense” and “AL-Sense” initially in Guatemala, with the other territories, - El Salvador, Honduras, Panama, Costa Rica, Nicaragua, and the Dominican Republic to follow shortly thereafter. After a 3 month period where product preparation, naming and packaging issues were resolved, product has been transported and is nearing delivery with official launch expected in February 2018. The Central American and Caribbean region possesses a total population of over 50,000,000 where Windsor Pharmaceuticals SA has projected sales in excess of $3,000,000 in the second full year of launch for both of its licensed products “Al-Sense” and “VS-Sense”. Thereafter, market penetration increases and other products will be added. Focus group research with gynecologists in the region have indicated a strong demand for both products which coincides with growing global sales of these products, supporting the belief in the region that a company such as Windsor Pharmaceuticals SA with innovative specialty products can fill the current void in product offerings to the Obstetricians/Gynecologists. Sales are expected to commence in Q1 2018 now that the initial regu...